Bruce C. Haas

Bruce C. Haas

Of Counsel, New York

Bruce Haas has been with the Firm since 1983 and focuses his practice on complex patent litigation. Bruce has extensive courtroom experience and has served as lead trial counsel in patent infringement litigations involving pharmaceuticals and mechanical devices. He is known for his hard work and practical advice (IAM World's Leading Patent Practitioners 2016)  and for providing “practical solutions to difficult problems” (Legal 500, 2013), being “outstanding strategically and tactically,” having a “good understanding of business and legal considerations relative to the dispute he is handling” and being “a good communicator and extraordinarily responsive” (U.S. News – Best Lawyers, 2010-11).

Bruce has wide experience in contested patent office proceedings including inter partes review and post grant review proceedings, patent evaluations and opinion work.

Bruce has served as Managing Partner in both the Firm’s New York and Washington, D.C. offices.

What Others Say
  • “Outstanding IP litigator.” (LMG Life Sciences 2017)
  • "Bruce is very customer oriented and willing to work at any hour of the day. He provides practical advice on projects that require immediate attention. He is a long-range strategic thinker who can map out how a case should be handled from day one, but is also great at adapting when circumstances change." (IAM World's Leading Patent Professionals 2016)
  • [provides] “practical solutions to difficult problems” (Legal 500 2013) 
  • “Bruce Haas is outstanding strategically and tactically. He has good understanding of business and legal considerations relative to the dispute he is handling. He is a good communicator and extraordinarily responsive” (U.S. News – Best Lawyers 2010-2011)
  • “excellent” (Legal 500 2009)
Representative Matters
  • AstraZeneca against multiple defendants on a patent relating to a sustained release antipsychotic drug, Seroquel XR®.
  • LEO Pharma against Tolmar Inc. on patents relating to Taclonex®, a topical anti-psoriatic medication.
  • Unigene Laboratories and Upsher-Smith Laboratories on a patent to Fortical®, an osteoporosis drug.
  • AstraZeneca against Teva on patents relating to Seroquel®, an antipsychotic medicine.
  • UCB against Mylan, Dr. Reddy, Sandoz and Cobalt on patents relating to Keppra®, a leading epilepsy medicine.
  • ElringKlinger against Federal-Mogul on patents relating to automotive gaskets.
  • Pharmacia, G.D. Searle, and Monsanto against the University of Rochester on patents relating to the blockbuster drug Celebrex®.
  • Bristol-Myers Squibb against BenVenue on patents relating to the cancer drug Taxol®.
  • Husky Injection Molding against Mold Masters on patents relating to injection molding machines.
  • Monsanto Co. & Johnson Controls, Inc. against Continental Can on plastic bottle technology.
  • Cytec Industries against Toray Industries on aircraft composites.
  • Upsher Smith Laboratories against Schering Plough on potassium products.
  • Eltech Systems against Engelhard and Electrocatalytic Inc. on electrocatalytic cell technology.
  • Dupont against Akzo on high strength fiber (Kevlar®) technology.
Events / Publications
News & Press